A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
Takeda
Novartis
Dana-Farber Cancer Institute
7 Hills Pharma, LLC
Cancer Research UK
Quadriga Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
Children's Oncology Group
University of Chicago
National Cancer Institute (NCI)